Last reviewed · How we verify
Olumacostat Glasaretil Gel, 5.0%
Olumacostat Glasaretil Gel, 5.0% is a SOAT1 inhibitor Small molecule drug developed by Dermira, Inc.. It is currently in Phase 3 development for Acne vulgaris. Also known as: DRM01, DRM01B.
Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands.
Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands. Used for Acne vulgaris.
At a glance
| Generic name | Olumacostat Glasaretil Gel, 5.0% |
|---|---|
| Also known as | DRM01, DRM01B |
| Sponsor | Dermira, Inc. |
| Drug class | SOAT1 inhibitor |
| Target | SOAT1 (sterol O-acyltransferase 1) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
The drug is a topical SOAT1 inhibitor that decreases sebaceous gland lipid synthesis and sebum secretion. By reducing sebum production, it addresses the underlying pathophysiology of acne and other sebum-related skin conditions. This mechanism targets a key driver of acne pathogenesis without systemic absorption.
Approved indications
- Acne vulgaris
Common side effects
- Application site irritation
- Erythema
- Dryness
Key clinical trials
- A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris (PHASE3)
- A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris (PHASE3)
- A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olumacostat Glasaretil Gel, 5.0% CI brief — competitive landscape report
- Olumacostat Glasaretil Gel, 5.0% updates RSS · CI watch RSS
- Dermira, Inc. portfolio CI
Frequently asked questions about Olumacostat Glasaretil Gel, 5.0%
What is Olumacostat Glasaretil Gel, 5.0%?
How does Olumacostat Glasaretil Gel, 5.0% work?
What is Olumacostat Glasaretil Gel, 5.0% used for?
Who makes Olumacostat Glasaretil Gel, 5.0%?
Is Olumacostat Glasaretil Gel, 5.0% also known as anything else?
What drug class is Olumacostat Glasaretil Gel, 5.0% in?
What development phase is Olumacostat Glasaretil Gel, 5.0% in?
What are the side effects of Olumacostat Glasaretil Gel, 5.0%?
What does Olumacostat Glasaretil Gel, 5.0% target?
Related
- Drug class: All SOAT1 inhibitor drugs
- Target: All drugs targeting SOAT1 (sterol O-acyltransferase 1)
- Manufacturer: Dermira, Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Also known as: DRM01, DRM01B
- Compare: Olumacostat Glasaretil Gel, 5.0% vs similar drugs
- Pricing: Olumacostat Glasaretil Gel, 5.0% cost, discount & access